替吉奥胶囊单药三线治疗老年晚期结直肠癌的临床观察

目的评价替吉奥胶囊单药三线治疗老年晚期结直肠癌的有效性与安全性。方法观察32例明确诊断的老年晚期结直肠癌患者,接受三线替吉奥胶囊单药治疗。每治疗2个周期后按RECIST标准评价疗效,同时按CTCAE标准评价安全性,并观察无进展生存期。结果 32例患者中有4例因不良反应仅接受1周期化疗不能评价疗效,28例可评价患者中PR 7.14%(2/28),SD 46.43%(13/28),PD 46.43%(13/28)。严重不良反应包括:1例Ⅳ度骨髓抑制伴全消化道黏膜炎、1例Ⅲ度恶心伴厌食、2例Ⅲ度腹泻。余不良反应主要为皮肤色素沉着、转氨酶升高等,耐受性良好。随访至2011年11月,中位无进展生存期为3.3个月。结论替吉奥胶囊单药三线治疗老年晚期结直肠癌,有一定的疗效,给药方便,价格适中,不良反应可耐受,值得临床进一步探索。

Tegafur,gimeracil and oteracil potassium capsules as line-3 treatment in elderly patients with advanced colorectal cancer

Objective To evaluate the efficacy and safety of tegafur,gimeracil and oteracil potassium capsules as line-3 treatment in elderly patients with advanced colorectal cancer.Methods 32 elderly patients with advanced colorectal cancer received tegafur,gimeracil and oteracil potassium capsules as line-3 treatment.After every two cycles,therapeutic efficacy was evaluated according to RECIST version 1.1.Adverse reactions were assessed during treatment according to CTCAE version 3.0.The progression-free survival was observed.Results 4 patients who only received 1 cycle chemotherapy due to adverse reactions were ruled out of evaluation.In 28 evaluable patients,2 patients had partial responses(7.14%),13 patients had stable diseases(46.43%) and 13 patients had progressive diseases(46.43%).The serious adverse reactions were Ⅳ degree bone marrow suppression with total tract mucositis(1 patient),Ⅲ degree nausea with anorexia(1 patient) and Ⅲ degree diarrhea(2 patients).The other adverse reactions including pigmentation,transaminase increasing,etc.were well tolerated.All cases were followed up to November 2011,the median progression-free survival was 3.3 months.Conclusion Tegafur,gimeracil and oteracil potassium capsules as line-3 treatment in elderly patients with advanced clorectal cancer have advantages of good efficacy,convenient administration,moderate prices and well tolerance,which deserve further study.